Merck looks poised to challenge Gilead

April 11, 2014 5:10 AM

24 0

Merck looks poised to challenge Gilead

Gilead's hepatitis C medication Sovaldi may have more than angry lawmakers to contend with: Phase-II data for Merck's daily one-pill combination of MK-5172 and MK-8742 has analysts marking this drug as a potential rival to the $84,000 medication that has become famous both for its price and ability to purge patients of the HCV virus.

Merck's C-WORTHy was a randomized study among treatment-naïve genotype-1 patients. The study included one group which received the NS3/4A protease inhibitor MK-5172 and NS5a replication complex inhibitor MK-8742, without ribavirin for 24 or 12 weeks, and a second group which received the combination...

Read more

To category page